Abstract：White matter damage, characterized by demyelination due to the damage of oligodendrocyte precursor cells (OPCs), is the most common type of brain damage in preterm infants. Survivors are often subject to long-term neurodevelopmental sequelae because of the lack of effective treatment. In recent years, it has been found that cell transplantation has the potential for the treatment of white matter damage. OPCs are frequently used cells in cell transplantation therapy. With abilities of migration and myelinization, OPCs are the best seed cells for the treatment of white matter damage. Several studies have found that OPCs may not only replace impaired cells to reconstruct the structure and function of white matter, but also inhibit neuronal apoptosis, promote the proliferation of endogenous neural stem cells, and enhance the repairment of the blood-brain barrier. However, the clinical application of OPC transplantation therapy faces many challenges, such as the effectiveness, risk of tumorigenesis and immune rejection. With reference to these studies, this article reviewed the development of myelination, the obtainment of OPCs, the therapeutic mechanism as well as application research, and analyzed the current challenges of OPC transplantation, in order to provide a new direction for clinical treatment of white matter damage in preterm infants.
YUE Yan,ZHANG Li,QU Yi et al. Neuroprotective effects of oligodendrocyte precursor cells on white matter damage in preterm infants[J]. CJCP, 2018, 20(4): 326-331.
Scolding NJ, Pasquini M, Reingold SC, et al. Cell-based therapeutic strategies for multiple sclerosis[J]. Brain, 2017, 140(11):2776-2796.
[7]
Assinck P, Duncan GJ, Plemel JR, et al. Myelinogenic plasticity of oligodendrocyte precursor cells following spinal cord contusion injury[J]. J Neurosci, 2017, 37(36):8635-8654.
[8]
Chang YS, Ahn SY, Sung S, et al. Stem cell therapy for neonatal disorders:prospects and challenges[J]. Yonsei Med J, 2017, 58(2):266-271.
[9]
Chen LX, Ma SM, Zhang P, et al. Neuroprotective effects of oligodendrocyte progenitor cell transplantation in premature rat brain following hypoxic-ischemic injury[J]. PLoS One, 2015, 10(3):e115997.
[10]
Itoh K, Maki T, Lok J, et al. Mechanisms of cell-cell interaction in oligodendrogenesis and remyelination after stroke[J]. Brain Res, 2015, 1623:135-149.
[11]
Shih Y, Ly PTT, Wang J, et al. Glial and neuronal protein tyrosine phosphatase alpha (PTPα) regulate oligodendrocyte differentiation and myelination[J]. J Mol Neurosci, 2017, 62(3-4):329-343.
[12]
Luo F, Zhang J, Burke K, et al. The activators of cyclin-dependent kinase 5 p35 and p39 are essential for oligodendrocyte maturation, process formation, and myelination[J]. J Neurosci, 2016, 36(10):3024-3037.
[13]
Xiao D, Qu Y, Pan L, et al. microRNAs participate in the regulation of oligodendrocytes development in white matter injury[J]. Rev Neurosci, 2018, 29(2):151-160.
[14]
Tauheed AM, Ayo JO, Kawu MU. Regulation of oligodendrocyte differentiation:Insights and approaches for the management of neurodegenerative disease[J]. Pathophysiology, 2016, 23(3):203-210.
[15]
Huang J, Zhang L, Qu Y, et al. Histone acetylation of oligodendrocytes protects against white matter injury induced by inflammation and hypoxia-ischemia through activation of BDNF-TrkB signaling pathway in neonatal rats[J]. Brain Res, 2017.[Epub ahead of print]
[16]
Buser JR, Maire J, Riddle A, et al. Arrested preoligodendrocyte maturation contributes to myelination failure in premature infants[J]. Ann Neurol, 2012, 71(1):93-109.
[17]
Xie D, Shen F, He S, et al. IL-1β induces hypomyelination in the periventricular white matter through inhibition of oligodendrocyte progenitor cell maturation via FYN/MEK/ERK signaling pathway in septic neonatal rats[J]. Glia, 2016, 64(4):583-602.
[18]
Shiow LR, Favrais G, Schirmer L, et al. Reactive astrocyte COX2-PGE2 production inhibits oligodendrocyte maturation in neonatal white matter injury[J]. Glia, 2017, 65(12):2024-2037.
[19]
Goldman SA, Kuypers NJ. How to make an oligodendrocyte[J]. Development, 2015, 142(23):3983-3995.
[20]
Sharp J, Hatch M, Nistor G, et al. Derivation of oligodendrocyte progenitor cells from human embryonic stem cells[J]. Methods Mol Biol, 2011, 767:399-409.
[21]
Li M, Suzuki K, Kim NY, et al. A cut above the rest:targeted genome editing technologies in human pluripotent stem cells[J]. J Biol Chem, 2014, 289(8):4594-4599.
[22]
Fox IJ, Daley GQ, Goldman SA, et al. Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease[J]. Science, 2014, 345(6199):1247391.
[23]
Rodrigues GMC, Gaj T, Adil MM, et al. Defined and scalable differentiation of human oligodendrocyte precursors from pluripotent stem cells in a 3D culture system[J]. Stem Cell Reports, 2017, 8(6):1770-1783.
[24]
Li P, Li M, Tang X, et al. Accelerated generation of oligodendrocyte progenitor cells from human induced pluripotent stem cells by forced expression of Sox10 and Olig2[J]. Sci China Life Sci, 2016, 59(11):1131-1138.
[25]
Goldman SA, Nedergaard M, Windrem MS. Glial progenitor cell-based treatment and modeling of neurological disease[J]. Science, 2012, 338(6106):491-495.
[26]
Lu Y, Yang Y, Wang Z, et al. Isolation and culture of human oligodendrocyte precursor cells from neurospheres[J]. Brain Res Bull, 2015, 118:17-24.
[27]
Wang C, Luan Z, Yang Y, et al. High purity of human oligodendrocyte progenitor cells obtained from neural stem cells:suitable for clinical application[J]. J Neurosci Methods, 2015, 240:61-66.
[28]
Seo JH, Miyamoto N, Hayakawa K, et al. Oligodendrocyte precursors induce early blood-brain barrier opening after white matter injury[J]. J Clin Invest, 2013, 123(2):782-786.
Maki T, Maeda M, Uemura M, et al. Potential interactions between pericytes and oligodendrocyte precursor cells in perivascular regions of cerebral white matter[J]. Neurosci Lett, 2015, 597:164-169.
[31]
Yuen TJ, Silbereis JC, Griveau A, et al. Oligodendrocyte-encoded HIF function couples postnatal myelination and white matter angiogenesis[J]. Cell, 2014, 158(2):383-396.
[32]
Seo JH, Maki T, Maeda M, et al. Oligodendrocyte precursor cells support blood-brain barrier integrity via TGF-β signaling[J]. PLoS One, 2014, 9(7):e103174.
[33]
Webber DJ, van Blitterswijk M, Chandran S. Neuroprotective effect of oligodendrocyte precursor cell transplantation in a long-term model of periventricular leukomalacia[J]. Am J Pathol, 2009, 175(6):2332-2342.
[34]
Wang S, Bates J, Li X, et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination[J]. Cell Stem Cell, 2013, 12(2):252-264.
[35]
Dooves S, van der Knaap MS, Heine VM. Stem cell therapy for white matter disorders:don't forget the microenvironment![J]. J Inherit Metab Dis, 2016, 39(4):513-518.
[36]
Xu L, Ryu J, Hiel H, et al. Transplantation of human oligodendrocyte progenitor cells in an animal model of diffuse traumatic axonal injury:survival and differentiation[J]. Stem Cell Res Ther, 2015, 6:93.
[37]
Givogri MI, Galbiati F, Fasano S, et al. Oligodendroglial progenitor cell therapy limits central neurological deficits in mice with metachromatic leukodystrophy[J]. J Neurosci, 2006, 26(12):3109-3119.
[38]
Pan H, Gazarian A, Dubernard JM, et al. Transplant tolerance induction in newborn infants:mechanisms, advantages, and potential strategies[J]. Front Immunol, 2016, 7:116.
[39]
Griesemer AD, Sorenson EC, Hardy MA. The role of the thymus in tolerance[J]. Transplantation, 2010, 90(5):465-474.
[40]
Alizadeh A, Karimi-Abdolrezaee S. Microenvironmental regulation of oligodendrocyte replacement and remyelination in spinal cord injury[J]. J Physiol, 2016, 594(13):3539-3552.
[41]
Yao ZF, Wang Y, Lin YH, et al. Transplantation of PDGF-AA-overexpressing oligodendrocyte precursor cells promotes recovery in rat following spinal cord injury[J]. Front Cell Neurosci, 2017, 11:79.
[42]
Jantzie LL, Miller RH, Robinson S. Erythropoietin signaling promotes oligodendrocyte development following prenatal systemic hypoxic-ischemic brain injury[J]. Pediatr Res, 2013, 74(6):658-667.
[43]
Kataria H, Alizadeh A, Shahriary GM, et al. Neuregulin-1 promotes remyelination and fosters a pro-regenerative inflammatory response in focal demyelinating lesions of the spinal cord[J]. Glia, 2018, 66(3):538-561.
